VALFIX Transcatheter Mitral Valve Repair: Clarification Required
I cannot provide specific information about the "VALFIX" or "Valfox" procedure because this device does not appear in the provided evidence or established medical literature. The evidence provided exclusively discusses MitraClip (Abbott Vascular), which is the only FDA-approved transcatheter mitral valve repair (TMVr) system in the United States as of the guideline publications 1.
What the Evidence Actually Covers
The only FDA-approved edge-to-edge transcatheter mitral valve repair device discussed in these guidelines is MitraClip, which uses percutaneous edge-to-edge leaflet repair to approximate the anterior and posterior mitral valve leaflets, restoring coaptation and creating a double orifice valve 1.
Key Points About Available TMVr Technology:
For Primary Mitral Regurgitation:
- MitraClip was FDA-approved in 2013 for selected patients with primary MR based on EVEREST trials 1
- Indicated for high-risk surgical patients with degenerative MR 2
For Secondary Mitral Regurgitation:
- FDA indication expanded in March 2019 for symptomatic patients with:
- Moderate-to-severe or severe secondary MR (grade >III)
- LVEF 20-50%
- LV end-systolic dimension <70 mm
- Persistent symptoms despite maximally tolerated guideline-directed medical therapy 1
Clinical Evidence:
- COAPT trial demonstrated 47% reduction in mortality (29.1% vs 46.1% at 24 months) and 48% reduction in heart failure hospitalizations with MitraClip plus medical therapy versus medical therapy alone in appropriately selected patients with secondary MR 1
Critical Recommendation
If you are asking about a mitral valve repair procedure, you need to clarify the specific device name. Possible considerations:
- You may be referring to MitraClip (the established device)
- You may be asking about an investigational device not yet in widespread clinical use
- There may be a spelling error in the device name
The multidisciplinary heart team evaluation remains essential for any transcatheter mitral valve intervention, requiring structural imaging expertise, interventional cardiology, and cardiac surgery collaboration to determine optimal patient-specific therapy 1.